La chaîne d'options affiche les données clés des options sur actions de Thermo Fisher Scientific à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Thermo Fisher Scientific..

Thermo Fisher Scientific (NYSE:TMO) Stock, Chaîne d'Options

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMTOM N.V. ORD

Trimol Group Inc

THERMO FISHER SCIENTIFIC ORD

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) is preparing to release its quarterly earnings on Wednesday, 2024-10-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Thermo Fisher Scientific to report an earnings per share (EPS) of $5.25.
The market awaits Thermo Fisher Scientific's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.25, leading to a 3.44% increase in the share price on the subsequent day.
Here's a look at Thermo Fisher Scientific's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.12</td>
<td>4.71</td>
<td>5.64</td>
<td>5.61</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.37</td>
<td>5.11</td>
<td>5.67</td>
<td>5.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729609380_0.png" alt="eps graph" />
<h3>Tracking Thermo Fisher Scientific's Stock Performance</h3>
Shares of Thermo Fisher Scientific were trading at $595.37 as of October 21. Over the last 52-week period, shares are up 36.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Thermo Fisher Scientific</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Thermo Fisher Scientific.
The consensus rating for Thermo Fisher Scientific is Outperform, derived from 15 analyst ratings. An average one-year price target of $665.4 implies a potential 11.76% upside.
<h3>Peer Ratings Overview</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Danaher, IQVIA Hldgs and Agilent Technologies, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Danaher is favoring an Outperform trajectory, with an average 1-year price target of $283.42, suggesting a potential 52.4% downside.</li>
<li>The consensus among analysts is an Outperform trajectory for IQVIA Hldgs, with an average 1-year price target of $268.5, indicating a potential 54.9% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Agilent Technologies, with an average 1-year price target of $148.78, suggesting a potential 75.01% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Danaher, IQVIA Hldgs and Agilent Technologies, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thermo Fisher Scientific</td>
<td>Outperform</td>
<td>-1.37%</td>
<td>$4.35B</td>
<td>3.33%</td>
</tr>
<tr>
<td>Danaher</td>
<td>Outperform</td>
<td>-2.86%</td>
<td>$3.43B</td>
<td>1.76%</td>
</tr>
<tr>
<td>IQVIA Hldgs</td>
<td>Outperform</td>
<td>2.31%</td>
<td>$1.33B</td>
<td>5.56%</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td>Neutral</td>
<td>-5.62%</td>
<td>$855M</td>
<td>4.65%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Thermo Fisher Scientific ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
<h3>Get to Know Thermo Fisher Scientific Better</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Unraveling the Financial Story of Thermo Fisher Scientific</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3 months period, Thermo Fisher Scientific faced challenges, resulting in a decline of approximately -1.37% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Thermo Fisher Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.69% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Thermo Fisher Scientific's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.58%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.75.
<a href="https://www.benzinga.com/quote/TMO/earnings">To track all earnings releases for Thermo Fisher Scientific visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Outlook For Thermo Fisher Scientific

Redburn Atlantic initiates coverage on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy rating and announces Price Target of $680.

News

Price Target

Initiation

Analyst Ratings

Redburn Atlantic Initiates Coverage On Thermo Fisher Scientific with Buy Rating, Announces Price Target of $680

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week of Oct. 11:
NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): The utility company saw headlines during the week related <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41254312/hurricane-milton-descends-on-florida-analysts-warn-of-impact-on-disney-nexteras-flo">to Hurricane Milton</a> and power outages in the state of Florida, which likely increased interest from Benzinga readers. 
The company owns Florida Power &amp; Light, which has more than six million customers in Florida. A report said <a href="https://www.benzinga.com/news/24/10/41266095/hurricane-milton-knocks-out-power-for-over-2m-in-florida-nextera-energy-duke-energy-and-tampa-electr">over 900,000 lost power</a> after Hurricane Milton struck the state. While the power outages could have a short-term negative impact on the company, NextEra is also the owner of a renewable energy segment and should be able to recover from the hurricane impact over the long term.
The company is set to report third-quarter financial results on Oct. 23, which could provide more commentary on the storm's impact. The company has beaten analyst estimates for earnings per share in nine of the past 10 quarters and beaten revenue estimates in six of the past 10 quarters.
Shares were slightly up the past week, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, and are up over 30% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204.png" alt="" class="wp-image-591824" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Monolithic Power Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>): A chipmaker specializing in power management systems, Monolithic Power Systems continues to see elevated interest from Benzinga readers. 
The company appeared on the Stock Whisper Index<a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet"> two weeks ago</a> after Stifel increased its price target from $1,000 to $1,100 while maintaining a Buy rating.
The company is expected to report third-quarter financial results in October. The chipmaker has beaten analyst estimates for earnings per share in more than 10 straight quarters and beaten revenue estimates from analysts in six straight quarters. A strong earnings report could send shares higher.
Monolithic shares were up more than 2% on the week and are up over 57% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205.png" alt="" class="wp-image-591826" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205-768x384.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): The software company and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) owner is no stranger to the Stock Whisper Index, making frequent appearances on the list thanks to growing interest in cryptocurrency and the company's strategy of buying Bitcoin with cash and by raising funds.
The company recently <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">announced the newest release</a> of MicroStrategy ONE, which includes integrations with Microsoft Teams and has new features for its AI bot. While many know the company as a major Bitcoin owner, MicroStrategy's software segment helps bring in cash flow to fuel the Bitcoin purchases.
MicroStrategy&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857237/microstrategy-stock-climbs-after-bitcoin-purchase-heres-how-much-btc-michael-saylors-compa" target="_blank" rel="noreferrer noopener">recently announced it bought</a>&nbsp;$1.1 billion worth of Bitcoin bringing its total up to 244,800 Bitcoin. The company&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919378/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases" target="_blank" rel="noreferrer noopener">recently raised</a>&nbsp;over $800 million to redeem $500 million in senior secured notes and to buy additional Bitcoin.
MicroStrategy began buying Bitcoin in August 2020 and will continue to add more Bitcoin, as co-founder and Executive Chairman&nbsp;Michael Saylor&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/22/06/27865236/exclusive-michael-saylors-microstrategy-is-married-to-bitcoin-everything-else-in-the-world" target="_blank" rel="noreferrer noopener">previously told Benzinga.</a>
&#8220;We have a simple strategy and our strategy is we just acquire Bitcoin, and we hold the Bitcoin,&#8221; Saylor told Benzinga.
New leveraged and inverse ETFs targeting MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40930553/microstrategy-2x-leveraged-inverse-etfs-are-here-offer-unparalleled-access-to-microstrateg">also recently launched, </a>which could increase interest in the company.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206.png" alt="" class="wp-image-591827" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206-768x385.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>): The natural gas company saw increased interest from Benzinga readers over the trading week. The surge in interest could be related to natural gas being volatile related to increased tension in the Middle East. 
Cheniere Energy will report third-quarter financial results on Oct. 31. The company has beaten analyst estimates for earnings per share in six of the past seven quarters and beaten revenue estimates from analysts in eight of the past 10 quarters.
Cheniere shares have traded near 52-week highs, as seen on the chart below. The stock is up 13% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="498" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208.png" alt="" class="wp-image-591828" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208-768x383.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): The scientific instruments and life sciences company saw a surge in interest from readers during the week. 
The increased attention could be related to Stephens <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular">initiating coverage on the stock </a>with an Overweight rating and $680 price target. The analyst sees the company benefiting from contract services and the surging demand for GLP-1 weight loss drugs. 
Stephens also highlighted the company's disciplined M&amp;A strategy to help with long-term growth. Evercore ISI Group also recently<a href="https://www.benzinga.com/quote/TMO/analyst-ratings"> raised the price target</a> on the stock from $605 to $630 while maintaining an Outperform rating.
The company is set to report third-quarter financial results on Oct. 23. Thermo Fisher has beaten analyst estimates for earnings per share in seven of the past 10 quarters and beaten revenue estimates from analysts in seven of the past 10 quarters.
Thermo Fisher shares are up 0.5% over the past five days and up around 10% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209.png" alt="" class="wp-image-591830" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 13</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/09/40962321/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 20</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 27</a></li>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">October 4</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a" target="_blank" rel="noreferrer noopener">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet As The Federal Reserve Springs Into Action For First Time In 4 Years</a></li>
</ul>

Exclusives

Tech

Trading Ideas

$BTC

MPWR

MSTR

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 5 years by 2.11% on an annualized basis producing an average annual return of 16.12%. Currently, Thermo Fisher Scientific has a market capitalization of $226.51 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 5 years ago, it would be worth $2,133.77 today based on a price of $593.41 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728322209_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 12.9% since its last report. The company recently reported that it has 3.99 million shares sold short, which is 1.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728312314_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 5.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(TMO) - Analyzing Thermo Fisher Scientific's Short Interest

Thermo Fisher Scientific&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) one of the largest contract drug manufacturing sites in the U.S., has repeatedly been flagged for regulatory violations.
Thermo Fisher&#8217;s Greenville facility manufactures around 40 medicines, including Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) weight-loss <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35142181/weight-loss-drug-boom-has-another-ripple-effect-rapid-growth-expected-in-fill-finish-market" rel="noreferrer noopener">drug Wegovy (semaglutide)</a>.
Recently, Stephen&#8217;s analyst said that Thermo Fisher&#8217;s pharma services assets, especially its contract development and manufacturing organization (CDMO), are well positioned. The company is set to capitalize on growth opportunities in the injectables sector, driven by GLP-1 demand and biologics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular" rel="noreferrer noopener">drug substance production</a>.
Over the past decade, the Greenville plant has been cited for issues related to contamination prevention, including two incidents earlier this year, Reuters noted, citing FDA documents.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39930516/thermo-fisher-q2-earnings-marginal-revenue-dip-completes-olink-acquisition-lifts-annual-profit-outl" rel="noreferrer noopener">Thermo Fisher Q2 Earnings: Marginal Revenue Dip, Completes Olink Acquisition, Lifts Annual Profit Outlook</a>.
Despite these concerns, the FDA did not take regulatory action, stating that the issues had been resolved to its satisfaction and that there was no evidence that patients had been harmed as a result.
During a recent inspection in May, the FDA identified manufacturing problems with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Beyfortus. The respiratory syncytial virus (RSV) preventive drug for infants and toddlers scored <a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33262341/astrazeneca-sanofis-respiratory-syncytial-virus-treatment-scores-fda-approval-to-prevent-infectio" rel="noreferrer noopener">FDA approval in 2023</a>.
The Reuters report highlighted that the FDA identified 17 deficiencies during the Beyfortus audit, including insufficient visual inspections for particulate matter in injectable drugs and issues with staff handling of sterile components.
The agency noted that Thermo Fisher&#8217;s equipment sterilization procedures were inadequate, and visual inspections for injectable drug contaminants failed.
Thermo Fisher has since addressed these issues, providing the FDA with the necessary data on drug safety, including control over bubble size in injectable medications. However, experts remain concerned about the plant&#8217;s approach to quality control.
In July, Merck &amp; Co Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Phase 2b/3 trial (MK-1654-004) of&nbsp;clesrovimab (MK-1654) to protect infants from respiratory syncytial virus (RSV) disease met its primary safety <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39916077/merck-competes-with-sanofiastrazeneca-as-its-rsv-treatment-drug-meets-primary-goal-in-late-stage-" rel="noreferrer noopener">and efficacy endpoints</a>.
Price Action: TMO stock is down 0.39% at $598.59 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41182921/rivians-production-forecast-hits-bump-supply-shortage-sends-shares-tumbling" target="_blank" rel="noreferrer noopener">Rivian&#8217;s Production Forecast Hits Bump, Supply Shortage Sends Shares Tumbling</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses

Stephens initiated coverage on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) and cited the company as an industry leader in the broader life science tools/services/ diagnostics industry, with fiscal year 2023 sales of almost $42.9 billion.
The analyst highlights Thermo Fisher&#8217;s extensive product and service portfolio and its significant revenue base. Over the past decade, the company has expanded its presence in the biopharma sector through strategic mergers and acquisitions, enhancing its market exposure.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39930516/thermo-fisher-q2-earnings-marginal-revenue-dip-completes-olink-acquisition-lifts-annual-profit-outl" rel="noreferrer noopener">Thermo Fisher Q2 Earnings: Marginal Revenue Dip, Completes Olink Acquisition, Lifts Annual Profit Outlook</a>.
Thermo Fisher has around 18% share of the estimated total addressable market at more than $235 billion.
Stephens says disciplined M&amp;A strategy and organic growth opportunities have the potential to support a long runway for long-term growth and margin expansion.
Thermo Fisher&#8217;s pharma services assets, especially its contract development and manufacturing organization (CDMO), are well positioned in today&#8217;s market. The company is set to capitalize on growth opportunities in the injectables sector, driven by GLP-1 demand, and in biologics drug substance production, supported by the BIOSECURE bill.
Stephens analyst writes, &#8220;After a difficult couple of years for the broader LS tools complex, 2025 should be a better year, but we have tried to assume a gradual recovery in our estimates.&#8221;
Stephens initiated coverage with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/TMO/analyst-ratings" rel="noreferrer noopener">price target of $680</a>.
The company&#8217;s Practical Process Improvement (PPI) system fosters ongoing enhancements and plays a crucial role in realizing synergies from acquisitions.
However, pursuing larger mergers and acquisitions may face greater challenges due to Thermo Fisher&#8217;s large scale and the heightened scrutiny of an active Federal Trade Commission.
Despite this, Thermo Fisher&#8217;s diverse portfolio offers ample organic growth potential, and there are still M&amp;A opportunities, particularly in bioprocessing, cell and gene therapy markets, and related service areas, per the analyst.
Price Action: TMO stock is down 0.83% at $613.45 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41124391/qualcomm-partners-with-stmicroelectronics-to-boost-ai-powered-iot-connectivity" target="_blank" rel="noreferrer noopener">Qualcomm Partners With STMicroelectronics To Boost AI-Powered IoT Connectivity</a>.</li>
</ul>

Analyst Color

Equities

Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential

Evercore ISI Group analyst Vijay Kumar maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and raises the price target from $605 to $630.

Evercore ISI Group Maintains Outperform on Thermo Fisher Scientific, Raises Price Target to $630

Stephens &amp; Co. analyst Jacob Johnson initiates coverage on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight rating and announces Price Target of $680.

Stephens & Co. Initiates Coverage On Thermo Fisher Scientific with Overweight Rating, Announces Price Target of $680

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 17.5%. Currently, Thermo Fisher Scientific has a market capitalization of $232.98 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $5,003.28 today based on a price of $610.35 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727199022_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today

JP Morgan analyst Rachel Vatnsdal maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and raises the price target from $650 to $670.

JP Morgan Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $670

Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and raises the price target from $615 to $680.

Stifel Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $680

RBC Capital analyst Conor McNamara reiterates Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and maintains $767 price target.

Reiteration

RBC Capital Reiterates Outperform on Thermo Fisher Scientific, Maintains $767 Price Target

Morgan Stanley analyst Tejas Savant maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and raises the price target from $655 to $680.

Morgan Stanley Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $680

At today's event, Thermo Fisher Scientific highlighted:
<ul>
<li>Incredibly well-positioned industry leadership, with leading businesses that enable our customers' success
<ul>
<li>Our industry-leading businesses are benefited by total company scale and capabilities. &nbsp;</li>
</ul>
</li>
<li>Attractive end markets that are fueled by enduring long-term trends
<ul>
<li>Thermo Fisher is the industry leader serving an attractive $235 billion market with long-term market growth of 4% to 6%. &nbsp;</li>
</ul>
</li>
<li>Proven growth strategy drives share gain
<ul>
<li>High-impact innovation: enabling major scientific breakthroughs.</li>
<li>The trusted partner to our customers: enabling customer success with an excellent reputation and credibility built over a long period of time.</li>
<li>Unparalleled commercial engine: commercial advantage through deep engagement with customers wherever they are. &nbsp;</li>
</ul>
</li>
<li>Practical Process Improvement Business System (PPI) enables outstanding execution
<ul>
<li>PPI is the core of Thermo Fisher's culture, with a focus on continuous improvement that drives quality, productivity and customer allegiance and engages every colleague to find a better way, every day.</li>
<li>PPI delivers competitive advantage and drives differentiated financial performance. &nbsp;</li>
</ul>
</li>
<li>Delivering differentiated value creation for all our stakeholders
<ul>
<li>Industry leading businesses have a long-standing track record of value creation.</li>
<li>Disciplined approach to capital deployment, which consists of strategic M&amp;A and returning capital to shareholders, enables us to better serve our customers and create tremendous value for our shareholders.</li>
<li>Mission-led comprehensive CSR strategy delivers competitive advantage through our innovations for a cleaner planet, investments in colleagues and communities and our focus on impact and accountability. More details can be found in the most recent <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorporate.thermofisher.com%2Fcontent%2Fdam%2Ftfcorpsite%2Fdocuments%2Fcorporate-social-responsibility%2Fannual-reports%2F2023-CSR-Report.pdf&amp;esheet=54124207&amp;newsitemid=20240919299545&amp;lan=en-US&amp;anchor=CSR+Report&amp;index=1&amp;md5=043c86c39168bf774d5a27615ad0617f">CSR Report</a>. &nbsp;</li>
</ul>
</li>
<li>Outstanding track record of financial performance and an excellent long-term outlook
<ul>
<li>Thermo Fisher's proven growth strategy drives share gain, and its capital deployment approach creates tremendous value, positioning the company to deliver organic revenue growth of 7% to 9% and mid-teens adjusted EPS growth over the long term.</li>
</ul>
</li>
</ul>

Thermo Fisher Scientific Hosts 2024 Investor Day, Showcasing Industry-Leading Businesses, Proven Growth Strategy, And Strong Long-Term Financial Outlook

In the latest quarter, 9 analysts provided ratings for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $641.56, along with a high estimate of $675.00 and a low estimate of $600.00. Marking an increase of 2.49%, the current average surpasses the previous average price target of $626.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726491610_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Thermo Fisher Scientific among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$675.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$670.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$658.00</td>
<td>$648.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$660.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$664.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$615.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$632.00</td>
<td>$620.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$615.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$600.00</td>
<td>$615.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Thermo Fisher Scientific. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Thermo Fisher Scientific's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Thermo Fisher Scientific's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Thermo Fisher Scientific analyst ratings.</a>
<h2>About Thermo Fisher Scientific</h2>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Financial Insights: Thermo Fisher Scientific</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Challenges: Thermo Fisher Scientific's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -1.37%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Thermo Fisher Scientific's ROE stands out, surpassing industry averages. With an impressive ROE of 3.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Thermo Fisher Scientific's ROA excels beyond industry benchmarks, reaching 1.58%. This signifies efficient management of assets and strong financial health.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Thermo Fisher Scientific Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

B of A Securities analyst Derik De Bruin maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and raises the price target from $600 to $675.

B of A Securities Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $675

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 7.46% on an annualized basis producing an average annual return of 19.03%. Currently, Thermo Fisher Scientific has a market capitalization of $236.61 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 15 years ago, it would be worth $13,025.01 today based on a price of $619.86 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725904816_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $13,000 Today

Deep-pocketed investors have adopted a bearish approach towards Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TMO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Thermo Fisher Scientific. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 2 are puts, totaling $62,734, and 6 are calls, amounting to $487,222.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $530.0 to $710.0 for Thermo Fisher Scientific during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Thermo Fisher Scientific stands at 69.25, with a total volume reaching 268.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Thermo Fisher Scientific, situated within the strike price corridor from $530.0 to $710.0, throughout the last 30 days.
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725557565_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$96.6</td>
<td>$90.8</td>
<td>$93.0</td>
<td>$530.00</td>
<td>$167.4K</td>
<td style="text-align: right;">172</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$83.5</td>
<td>$82.0</td>
<td>$82.0</td>
<td>$550.00</td>
<td>$147.6K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$43.4</td>
<td>$41.6</td>
<td>$43.2</td>
<td>$590.00</td>
<td>$69.1K</td>
<td style="text-align: right;">59</td>
<td style="text-align: right;">37</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$650.00</td>
<td>$37.7K</td>
<td style="text-align: right;">73</td>
<td style="text-align: right;">112</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$37.5</td>
<td>$34.8</td>
<td>$36.39</td>
<td>$710.00</td>
<td>$36.5K</td>
<td style="text-align: right;">54</td>
<td style="text-align: right;">32</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Following our analysis of the options activities associated with Thermo Fisher Scientific, we pivot to a closer look at the company's own performance.
<h3>Where Is Thermo Fisher Scientific Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 593,628, with TMO's price down by -0.01%, positioned at $611.84.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $670.0.
<ul>
<li>An analyst from Wells Fargo downgraded its action to Overweight with a price target of $670. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Spotlight on Thermo Fisher Scientific: Analyzing the Surge in Options Activity

Wells Fargo analyst Brandon Couillard initiates coverage on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight rating and announces Price Target of $670.

Wells Fargo Initiates Coverage On Thermo Fisher Scientific with Overweight Rating, Announces Price Target of $670

Dividend Champion, Contender, And Challenger Highlights: Week Of October 13

SA Asks: Which stocks would be most impacted by increased tariffs?

IYH: Healthcare Dashboard For October

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Danaher (DHR – Research Report) and Thermo Fisher (T...

Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Thermo Fisher (TMO)

RBC Capital analyst Conor McNamara maintained a Buy rating on Thermo Fisher (TMO – Research Report) on October 14 and set a price target of $767.00...

Thermo Fisher (TMO) Gets a Buy from RBC Capital

The health and wellness market is experiencing growth due to the rising prevalence of chronic diseases, increased consumer demand for health products, and substantial sales growth in health insurance and consumer healthcare markets. Therefore, it could be wise to watch top health and wellness stocks: UnitedHealth Group (UNH), Thermo Fisher Scientific (TMO), and Herbalife (HLF). Read on... The rising prevalence of chronic diseases is driving demand for health insurance products and increasing investments in chronic disease management research. This trend is also shifting consumer preferences towards health-oriented goods, making the health and wellness sector a strong market opportunity.
Against this backdrop, it could be wise to watch top health and wellness stocks such as UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>), Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>), and Herbalife Ltd. (<a href="https://stocknews.com/stock/HLF/">HLF</a>).
Healthcare expenses have risen steadily, with increasing awareness of health issues prompting insurers to include these services in their policies. This shift reflects consumer demand for comprehensive wellness solutions and ensures that health expenditures remain a priority across economic cycles. Consequently, the global health insurance market is projected to reach <a href="https://www.statista.com/outlook/fmo/insurances/non-life-insurances/health-insurance/worldwide#:~:text=The%20Health%20insurance%20market%20market,to%20US%24306.70%20in%202024.">$2.38 trillion this year</a>.
Meanwhile, companies are increasingly focusing on innovations in personalized medicine and diagnostic tools to improve preventive care, leading to better health outcomes and reduced long-term costs. This segment is set to grow, emphasizing early detection and tailored healthcare solutions. For 2024, R&amp;D World forecasts a global investment of <a href="https://www.rdworldonline.com/research-development-2024-global-rd-investment-forecast/#:~:text=A%20look%20at%20global%20R&amp;D,the%20growing%20share%20of%20GDP.%E2%80%9D">$2.53 trillion in R&amp;D</a>, an 8.3% increase from the 2022 forecast.
Furthermore, there is a notable shift towards health-oriented consumer goods, such as nutritional supplements, organic foods, and personal care products, reflecting changing consumer preferences for healthier options. With consumers increasingly investing in wellness, the global consumer healthcare market is projected to exceed $708.44 billion by 2034, growing at a <a href="https://www.precedenceresearch.com/consumer-healthcare-market">CAGR of 7.9%</a>.
Considering these conducive trends, let's analyze the fundamentals of the three health and wellness picks mentioned above.
UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>)
UNH operates as a diversified healthcare company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and OptumRx.
On August 13, 2024, UNH announced it will continue serving Florida Medicaid members through 2030 in 30 counties. The company will work with the Florida Agency for Health Care Administration (AHCA) to provide various healthcare services.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a>, UNH's 8.89% is 42.9% higher than the 6.22% industry average. Likewise, its 1.36x trailing-12-month asset turnover ratio is 229.7% higher than the 0.41x industry average. Its 8.18% trailing-12-month EBIT margin is 207.8% higher than the 2.66% industry average.
During the third quarter that ended September 30, 2024, UNH's total revenues increased 9.2% year-over-year to $100.82 billion. The company's earnings from operations came in at $8.71 billion, up 2.1% from the year-ago value.
Moreover, its adjusted net earnings attributable to UNH common shareholders came in at $6.65 billion and $7.15 per share, up 8.4% and 9% from the previous year's quarter, respectively.
Street expects UNH's EPS and revenue for the quarter ending December 31, 2024, to increase 10.1% and 7.7% year-over-year to $6.78 and $101.65 billion, respectively. It surpassed Street EPS estimates in each of the trailing four quarters. Over the past six months, the stock has gained 19.9% to close the last trading session at $562.05.
UNH's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #4 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry. It has a B grade for Stability and Sentiment. <a href="https://stocknews.com/stock/UNH/">Click here</a> to see UNH's ratings for Growth, Value, Momentum, and Quality.
Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>)
TMO provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates in four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
On July 11, 2024, TMO announced its partnership with the National Cancer Institute to accelerate myeloid cancer research through the myeloMATCH precision medicine trial, utilizing next-generation sequencing for rapid patient matching to clinical trials. This initiative aims to improve treatment options for Acute Myeloid Leukemia and Myelodysplastic Syndrome by quickly identifying specific genetic biomarkers.
In terms of the trailing-12-month levered FCF margin, TMO's 15.39% is 917.2% higher than the 1.51% industry average. Its 0.44x trailing-12-month asset turnover ratio is 7% higher than the 0.41x industry average. Similarly, the stock's 17.58% trailing-12-month EBIT margin is 562.1% higher than the 2.66% industry average.
For the second quarter of 2024, which ended on June 29, TMO's revenues were $10.54 billion, and operating income for the same period increased 15.3% year-over-year to $1.82 billion. Also, its adjusted net income and adjusted EPS for the quarter amounted to $2.06 billion and $5.37, representing an increase of 3% and $0.43 from the same period last year.
For the quarter ended September 30, 2024, TMO's revenue is expected to increase marginally year-over-year to $10.63 billion. Its EPS for the quarter ending December 31, 2024, is expected to grow 5.3% year-over-year to $5.97. It surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 23.8% to close the last trading session at $604.55.
TMO's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It has a B grade for Stability and Sentiment. It is ranked #5 out of 40 stocks in the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical - Diagnostics/Research</a> industry. To access additional grades for TMO's Growth, Value, Momentum, and Quality ratings, <a href="https://stocknews.com/stock/TMO/">click here</a>.
Herbalife Ltd. (<a href="https://stocknews.com/stock/HLF/">HLF</a>)
HLF provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers products in the areas of weight management, targeted nutrition, energy, sports and fitness, outer nutrition, and literature and promotional items.
In terms of the trailing-12-month Return on Total Capital, HLF's 15.83% is 130.2% higher than the 6.88% industry average. Likewise, its 44.41% trailing-12-month gross profit margin is 23.9% higher than the 35.84% industry average. However, its 10.41% trailing-12-month EBITDA margin is 18.5% lower than the 12.77% industry average.
In the second quarter that ended June 30, 2024, HLF's worldwide net sales reached $1.28 billion, down 2.5% year-over-year. For the same quarter, its operating income declined by 34.8% compared to the prior year, totaling $80.40 million. Moreover, as of June 30, 2024, the company's total liabilities stood at $3.64 billion, compared to $3.87 billion as of December 31, 2023.
Analysts expect HLF's revenue for the quarter ending March 31, 2025, to increase 2.2% year-over-year to $1.29 billion. Likewise, its EPS for fiscal 2025 is expected to increase 32.8% year-over-year to $2.01. Over the past month, the stock has declined 2.7% to close the last trading session at $6.87.
HLF's mixed fundamentals are reflected in its POWR Ratings. It has an overall rating of C, which translates to a Neutral in our proprietary rating system.
It has a C grade for Stability. Within the A-rated <a href="https://stocknews.com/category/medical-consumer-goods/">Medical - Consumer Goods</a> industry, it is ranked #7 out of 9 stocks. To see HLF's Growth, Value, Momentum, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/HLF/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
UNH shares were trading at $568.43 per share on Thursday afternoon, down $2.91 (-0.51%). Year-to-date, UNH has gained 9.24%, versus a 23.79% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/unh-tmo-hlf-3-stocks-to-watch-in-the-health-and-wellness-sector/>3 Stocks to Watch in the Health and Wellness Sector</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Stocks to Watch in the Health and Wellness Sector

Baron Health Care Fund Q3 2024 Shareholder Letter

UBS upgrades view on U.S. stocks to attractive - here are its top picks

Earnings week ahead: TSLA, GE, GM, KO, PM, LUV, AAL, VZ, T and more

ABBV

ACLX

ADBE

AGNC

ALKS

AMGN

ARGNF

ARGX

AROW

AVNT

BANF

BCAP

BMYMP

BROE

CHCO

CINF

COLL

CSWI

CTRE

CTVA

CUBE

DXCM

ENPH

ESRT

EXEL

FITB

FLIC

FMAO

FMAT

FNLC

FUNC

GAIN

GEHC

GSBC

GWRS

HBNC

HRMY

ICLR

IIPR

INSM

INTU

INVA

INVH

IROQ

IRTC

ISRG

LECO

LRCX

LULU

MGRC

MSFT

NVDA

NWFL

OTIS

PCVX

RARE

RBCAA

RDNT

REGN

REXR

RGCO

RGLD

ROST

RSPH

SCVL

SPXU

STAG

TFII

THFF

TMUS

TREX

TSLA

TYBT

TYCB

UPRO

VALE

VRTX

WDFC

XLRE

YORW

Press Releases

Thermo Fisher Scientific Declares Quarterly Dividend

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Thermo Fisher Scientific Reports Second Quarter 2024 Results

Small Cap

Opinion

Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth

Thermo Fisher Scientific to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024

Thermo Fisher Scientific Hosts 2024 Investor Day

Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements

"Nasdaq Stocks Set for Explosive Growth: BNZI, SEEL, PRSO, MSS, HSCS Revamp for Big Potential"

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 23, 2024

BATL

BDTX

BNZI

BVAXF

CSE:BIOV

HSCS

KAVL

NEOG

PRSO

RHHBY

SEEL

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Comments

Thermo Fisher Scientific

Thermo Fisher Scientific (TMO) Options

Thermo Fisher Scientific (NYSE:TMO) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL